statistiche ricercatore

BARTALENA, LUIGI

Distribuzione geografica

Continente	#
NA - Nord America	30.073
EU - Europa	14.664
AS - Asia	9.466
SA - Sud America	977
Continente sconosciuto - Info sul continente non disponibili	293
AF - Africa	211
OC - Oceania	25
AN - Antartide	1
Totale	55.710

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	29.716
IT - Italia	6.693
SG - Singapore	2.804
UA - Ucraina	2.452
CN - Cina	2.024
TR - Turchia	1.438
VN - Vietnam	1.374
DE - Germania	1.016
HK - Hong Kong	999
SE - Svezia	992
BR - Brasile	784
FI - Finlandia	737
IE - Irlanda	701
GB - Regno Unito	671
FR - Francia	495
RU - Federazione Russa	426
BD - Bangladesh	233
CA - Canada	176
IN - India	174
JP - Giappone	112
NG - Nigeria	101
MX - Messico	92
NL - Olanda	66
AR - Argentina	62
PL - Polonia	56
ES - Italia	51
AT - Austria	47
IQ - Iraq	45
EU - Europa	41
BE - Belgio	38
CZ - Repubblica Ceca	38
ZA - Sudafrica	33
CL - Cile	32
ID - Indonesia	32
LT - Lituania	29
PK - Pakistan	29
EC - Ecuador	28
CH - Svizzera	23
IL - Israele	23
MY - Malesia	22
UZ - Uzbekistan	22
CO - Colombia	20
PH - Filippine	17
RO - Romania	16
AE - Emirati Arabi Uniti	15
SA - Arabia Saudita	15
VE - Venezuela	15
HN - Honduras	14
KE - Kenya	14
MD - Moldavia	14
CR - Costa Rica	13
EG - Egitto	13
JM - Giamaica	13
NZ - Nuova Zelanda	13
MA - Marocco	12
NP - Nepal	12
PY - Paraguay	12
AU - Australia	11
HU - Ungheria	10
BG - Bulgaria	9
BY - Bielorussia	9
PE - Perù	9
TH - Thailandia	9
TT - Trinidad e Tobago	9
AZ - Azerbaigian	8
DZ - Algeria	8
TN - Tunisia	8
BO - Bolivia	7
DK - Danimarca	7
EE - Estonia	7
KR - Corea	7
MT - Malta	7
RS - Serbia	7
HR - Croazia	6
NI - Nicaragua	6
NO - Norvegia	6
PT - Portogallo	6
UY - Uruguay	6
BA - Bosnia-Erzegovina	5
DO - Repubblica Dominicana	5
GR - Grecia	5
IR - Iran	5
LU - Lussemburgo	5
OM - Oman	5
BB - Barbados	4
CI - Costa d'Avorio	4
GT - Guatemala	4
JO - Giordania	4
KG - Kirghizistan	4
PA - Panama	4
SK - Slovacchia (Repubblica Slovacca)	4
SN - Senegal	4
SV - El Salvador	4
AL - Albania	3
AM - Armenia	3
BN - Brunei Darussalam	3
KW - Kuwait	3
LB - Libano	3
LK - Sri Lanka	3
MM - Myanmar	3
Totale	55.404

Salva come PNG Salva come JPEG

Città	#
Milan	4.599
Fairfield	3.211
Ashburn	2.328
San Jose	2.167
Jacksonville	1.896
Woodbridge	1.869
Chandler	1.659
Singapore	1.451
Houston	1.377
Seattle	1.335
Wilmington	1.245
Cambridge	1.075
Dearborn	1.072
Hong Kong	978
Ann Arbor	969
Dallas	963
Council Bluffs	926
Izmir	724
Dublin	689
Princeton	674
Beijing	439
Nyköping	416
Dong Ket	408
The Dalles	398
Boardman	397
Chicago	383
Rome	377
Lauterbourg	319
New York	264
Como	238
San Mateo	237
San Diego	205
Ho Chi Minh City	198
Los Angeles	194
Santa Clara	164
Helsinki	160
Hanoi	143
Ogden	124
London	113
Guangzhou	103
Abuja	100
Orem	100
Tokyo	96
São Paulo	90
Düsseldorf	86
Hefei	83
Zhengzhou	78
Washington	77
Kunming	76
Shanghai	72
Munich	63
Norwalk	61
Kocaeli	60
Nanjing	60
Frankfurt am Main	55
Phoenix	55
Mexico City	54
Buffalo	52
Redmond	52
Chennai	50
Warsaw	46
Brooklyn	45
Montreal	45
Atlanta	43
Denver	41
Toronto	41
Stockholm	37
Brussels	36
Hangzhou	36
San Francisco	36
Manchester	34
Verona	34
Jinan	33
Shenzhen	30
Tianjin	30
Brno	28
Amsterdam	26
Haiphong	26
Nanchang	26
Vienna	26
Da Nang	25
Naples	24
Poplar	23
Austin	22
Johannesburg	22
Paris	22
Pune	22
Rio de Janeiro	22
Charlotte	21
Miami	21
North Bergen	21
Baghdad	19
Boston	19
Nuremberg	19
Tampa	19
Tashkent	19
Turku	19
Kilburn	18
Madrid	18
Mumbai	18
Totale	39.019

Salva come PNG Salva come JPEG

Nome	#
The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy	372
Vitreous Substitutes: The Present and the Future.	301
A teleconsultation network improves the efficacy of anti-VEGF therapy in retinal diseases.	290
Graves' ophthalmopathy	290
Macular hole surgery: The healing process of outer retinal layers to visual acuity recovery	288
Iopanoic acid rapidly controls Type I amiodarone-induced thyrotoxicosis prior to thyroidectomy	284
The phenotype of newly diagnosed Graves’ disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study	268
Process to radioactive iodine treatment for Graves' hyperthyroidism: condemned or absolved?	263
Simultaneous medullary and papillary thyroid cancer: two case reports.	261
Antithyroid drug treatment for Graves’ disease: baseline predictive models of relapse after treatment for a patient-tailored management	259
Masked hypertension in newly diagnosed hypothyroidism: a pilot study	258
A 2013 European survey of clinical practice patterns in the management of Graves' disease	252
Cardiometabolic healthy and unhealthy obesity: does vitamin D play a role?	248
Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-sectional study	239
The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study	238
Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European Endocrinologists	236
Effects of selenium on short-term control of hyperthyroidism due to Graves' disease treated with methimazole: results of a randomized clinical trial	234
The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy	232
Immunomodulatory effect of vitamin D and its potential role in the prevention and treatment of thyroid autoimmunity: a narrative review	229
Consensus Statement of the European Group on Graves' Orbitopathy (EUGOGO) on Management of Graves' Orbitopathy	228
Absence of serum thyroid hormone autoantibodies in patients chronically treated with amiodarone	226
Graves' hyperthyroidism of recent onset and Graves' orbitopathy: to ablate or not to ablate the thyroid?	223
Pituitary apoplexy during pregnancy: A rare, but dangerous headache	223
Features and outcome of differentiated thyroid carcinoma associated with Graves' disease: results of a large, retrospective, multicenter study	223
Can combination of glucocorticoids with other immunosoppressive drugs reduce the cumulative dose of glucocorticoids for moderate-to-severe and active Graves' orbitopathy?	222
PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012	220
Outcome prediction of treatment of Graves' hyperthyroidism with antithyroid drugs	219
Oral steroid prophylaxis for Graves' orbitopathy after radioactive iodine treatment for Graves' disease is not only effective, but also safe	219
Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association	218
Can a patient-tailored treatment approach for Graves' disease reduce mortality?	218
Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO	217
Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves' orbitopathy: a retrospective cohort study	215
Nutrizione iodica e ipertiroidismo: quello che c’è da sapere	214
Time interval in diagnosis and treatment of papillary thyroid cancer: a descriptive, retrospective study	212
Amiodarone iodine-induced hypothyroidism: risk factors and follow-up in 28 cases	211
Pain perception, blood pressure levels, and peripheral benzodiazepine receptors in patients followed for differentiated thyroid carcinoma: a longitudinal study in hypothyroidism and during hormone treatment	210
Purification and partial characterization of a novel thyroxine-binding protein (27 K protein) from human plasma	209
Thyroid hormone treatment for differentiated thyroid carcinoma: What drug, how long, what dose?	209
Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves’ Disease Hyperthyroidism During Methimazole Treatment	209
Physical performance in newly diagnosed hypothyroidism: a pilot study	207
The presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 amiodarone-induced thyrotoxicosis.	205
Characteristics of a nationwide cohort of patients presenting with isolated hypogonadotropic hypogonadism (IHH)	205
An update on medical management of Graves' ophthalmopathy	204
Plasma total and acylated ghrelin concentrations in patients with clinical and subclinical thyroid dysfunction	204
Graves' orbitopathy: do not give it for granted	203
Serum TSH measurements by a sensitive enzyme immunoassay discriminate euthyroid from hyperthyroid subjects and avoid the need for TRH test during suppressive therapy with L-thyroxine	202
Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal	202
Adjuvant effect of lithium on radioiodine treatment of hyperthyroidism	201
The clinical enigma of the “Flea catcher” by Georges de La Tour: a pregnant sinner with pre-eclampsia or a hypothyroid girl?	201
Novel treatment modalities for Graves' orbitopathy	199
Lack of nocturnal serum thyrotropin surge after surgery	198
Radioactive iodine thyroid uptake in patients with amiodarone iodine-induced thyroid dysfunction	198
The effect of altered thyroid function on serum fructosamine concentrations	196
Medullary thyroid carcinoma: surgical treatment advances	196
Proportion of type 1 and type 2 amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy	195
Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves’ orbitopathy?	195
Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.	194
Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed Graves' hyperthyroidism seen at a single center	194
Iodine supplementation in women of reproductive age: a survey of clinical practice among Italian gynecologists and midwives	194
Interference of thyroglobulin in TSAb detection by radioreceptor assay	193
2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction	193
Studies on the occurrence of ophthalmopathy in Graves' disease	192
More on smoking habits and Graves' ophthalmopathy	192
Thyroid vascularity and blood flow are not dependent on serum thyroid hormone levels:studies in vivo by color flow Doppler sonography	192
Amiodarone and the thyroid	192
Characterization of nascent and secreted thyroxine-binding globulin in cultured human hepatoma (Hep G2) cells	191
Gastric Xanthomatous Hyperplastic Polyps – Just an Incidental Endoscopic Finding?	190
Management of Graves' ophthalmopathy: reality and perspectives	189
Recommendations for treatment of hypothyroidism with levothyroxine and levotriiodothyronine: a 2016 position statement of the Italian Society of Endocrinology and the Italian Thyroid Association	189
Predictive score for the development or progression of Graves' orbitopathy in patients with newly diagnosed Graves' hyperthyroidism	189
Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: Results of a prospective, single-blind, randomized study	188
Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids	188
Free thyroxine values in dried blood spots on filter paper in newborns are related to both gestational age and birth body weight	187
Diagnosis of amiodarone iodine-induced thyrotoxicosis (AIIT) associated with severe nonthyroidal illness	187
Orbital radiotherapy for Graves' ophthalmopathy	187
Human serum thyrotrophin measurement by ultrasensitive immunoradiometric assay as a first-line test in the evaluation of thyroid function	186
Maria Carolina of Austria, Queen of Naples and Sicily: a possible case of Graves' orbitopathy	186
Graves' disease and Turner's syndrome	185
Graves'-like orbitopathy: do not forget IgG4-related disease	183
Comparison between thyroid-stimulating and TSH-binding inhibiting immunoglobulins of Graves' disease	182
Shortening Hospital Stay for Thyroid Surgery.	182
Graves' orbitopathy: imperfect treatments for a rare disease	182
2018 European thyroid association guideline for the management of graves' hyperthyroidism	182
The age of patients with thyrotoxicosis factitia in Italy from 1973 to 1996	181
Thyroid hormone regulation of cell migration and oxidative metabolism in polymorphonuclear leukocytes: clinical evidence in thyroidectomized subjects on thyroxine replacement therapy.	181
Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy	180
Effects of treatment modalities for Graves' hyperthyroidism on Graves' orbitopathy: a 2015 Italian Society of Endocrinology consensus statement	180
Factors affecting suppression of endogenous thyrotropin secretion by thyroxine treatment: retrospective analysis in athyreotic and goitrous patients	179
Radioimmunoassay of thyroid hormones	178
Effects of the antileukemic drug L-asparaginase on sex-hormone binding globulin: studies in vivo and in vitro	178
Effect of the antileukemic agent L-asparaginase on thyroxine-binding globulin and albumin synthesis in cultured human hepatoma (Hep G2) cells	178
An update on the pharmacological management of hyperthyroidism due to Graves' disease	178
Thyroid hormone and thyrotropin regulate intracellular free calcium concentrations in human polymorphonuclear leukocytes: in vivo and in vitro studies	178
Biosynthesis of a novel thyroxine-binding protein (27 K protein) in human hepatoma (Hep G2) cells	177
Changes in radioimmunoassayable prealbumin (TBPA) serum levels from birth to adulthood	177
Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement	177
Guida dei farmaci e delle sostanze interferenti sulla funzione tiroidea	176
Potassium perchlorate only temporarily restores euthyroidism in patients with amiodarone-induced hypothyroidism who continue amiodarone therapy	176
Effect of amiodarone on circulating antithyroid antibodies	176
Oxidative stress and Graves' ophthalmopathy: In vitro studies and therapeutic implications	176
Totale	20.913

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	223.083
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	223.083

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	2.478	0	0	0	133	196	144	175	183	265	569	306	507
2022/2023	4.398	496	246	391	422	319	949	4	540	582	150	178	121
2023/2024	7.478	1.101	1.179	1.141	1.443	1.532	496	52	157	188	54	23	112
2024/2025	4.421	20	64	889	105	103	243	200	365	466	292	342	1.332
2025/2026	11.354	693	730	747	1.311	1.010	549	2.526	706	1.360	720	577	425
2026/2027	3.094	311	752	1.726	305	0	0	0	0	0	0	0	0
Totale													55.710